ATE346094T1 - Synthetische humane peptide und diese enthaltende pharmazeutische zusammensetzungen zur behandlung von systemischem lupus erythematodes - Google Patents

Synthetische humane peptide und diese enthaltende pharmazeutische zusammensetzungen zur behandlung von systemischem lupus erythematodes

Info

Publication number
ATE346094T1
ATE346094T1 AT02700553T AT02700553T ATE346094T1 AT E346094 T1 ATE346094 T1 AT E346094T1 AT 02700553 T AT02700553 T AT 02700553T AT 02700553 T AT02700553 T AT 02700553T AT E346094 T1 ATE346094 T1 AT E346094T1
Authority
AT
Austria
Prior art keywords
systemic lupus
erythematode
treatment
pharmaceutical compositions
compositions containing
Prior art date
Application number
AT02700553T
Other languages
English (en)
Inventor
Edna Mozes
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE346094T1 publication Critical patent/ATE346094T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02700553T 2001-02-26 2002-02-26 Synthetische humane peptide und diese enthaltende pharmazeutische zusammensetzungen zur behandlung von systemischem lupus erythematodes ATE346094T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL14164701A IL141647A0 (en) 2001-02-26 2001-02-26 Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
ATE346094T1 true ATE346094T1 (de) 2006-12-15

Family

ID=11075174

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02700553T ATE346094T1 (de) 2001-02-26 2002-02-26 Synthetische humane peptide und diese enthaltende pharmazeutische zusammensetzungen zur behandlung von systemischem lupus erythematodes

Country Status (28)

Country Link
US (2) US20040127408A1 (de)
EP (1) EP1370575B1 (de)
JP (1) JP4316886B2 (de)
KR (1) KR100860735B1 (de)
CN (1) CN1309733C (de)
AT (1) ATE346094T1 (de)
AU (1) AU2002233618B2 (de)
BR (1) BR0207586A (de)
CA (1) CA2439051C (de)
CR (1) CR7058A (de)
CU (1) CU23276B7 (de)
DE (1) DE60216243T2 (de)
DK (1) DK1370575T3 (de)
EA (1) EA009465B1 (de)
EC (1) ECSP034743A (de)
ES (1) ES2275832T3 (de)
HR (1) HRP20030667A2 (de)
HU (1) HU230372B1 (de)
IL (3) IL141647A0 (de)
IS (1) IS6908A (de)
MX (1) MXPA03007622A (de)
NO (1) NO331820B1 (de)
NZ (1) NZ527499A (de)
PL (1) PL373520A1 (de)
PT (1) PT1370575E (de)
SI (1) SI1370575T1 (de)
WO (1) WO2002067848A2 (de)
ZA (1) ZA200305874B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001292846A1 (en) * 2000-09-20 2002-04-29 Surromed, Inc. Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders
IL141647A0 (en) 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
KR20050100616A (ko) * 2003-01-14 2005-10-19 테바 파마슈티컬 인더스트리즈 리미티드 전신성 홍반성 낭창의 치료를 위한 펩티드의 비경구 제제
EP1594434B1 (de) * 2003-01-14 2016-09-07 Yeda Research and Development Co. Parenterale peptidformulierungen zur behandlung von systemischem lupus erythematodes
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US8313950B2 (en) * 2007-05-21 2012-11-20 The Ohio State University Research Foundation Hepcidins as biomarkers for impending lupus nephritis flare
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
KR20140088837A (ko) 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
EP3052526A4 (de) 2013-10-03 2017-04-19 Oregon Health & Science University Rekombinante polypeptide mit mhc-klasse-ii-1-domänen
WO2018127914A1 (en) 2017-01-05 2018-07-12 Yeda Research And Development Co. Ltd. Peptides for treating sjogren's syndrome
CN112143707A (zh) * 2020-09-29 2020-12-29 广东先康达生物科技有限公司 一种治疗自身免疫细胞的免疫细胞及其应用
WO2025008818A1 (en) * 2023-07-03 2025-01-09 Dan Goldstaub Compositions and methods for treatment of systemic lupus erythematosus
WO2025027013A1 (en) * 2023-08-01 2025-02-06 Diamante Srl Composition and methods for treating system lupus erythematosus

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US127408A (en) * 1872-06-04 Improvement in tooth-powders or dentifrices
US8634A (en) * 1852-01-06 Wool-pickina machine
JPS60184098A (ja) * 1984-03-02 1985-09-19 Suntory Ltd 新規なペプチド及びこれを有効成分とする利尿剤
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5126249A (en) * 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
US6066621A (en) * 1989-12-10 2000-05-23 Yeda Research And Development Co. Ltd. Synthetic peptides for the treatment of myasthenia gravis
IL92629A0 (en) * 1989-12-10 1990-08-31 Yeda Res & Dev Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9017008D0 (en) 1990-08-02 1990-09-19 Erba Carlo Spa Process for the enzymatic preparation of basic fibroblast growth factor
US6096878A (en) * 1993-05-10 2000-08-01 Japan Tobacco Inc. Human immunoglobulin VH gene segments and DNA fragments containing the same
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
GB2290293A (en) * 1994-06-08 1995-12-20 Rupert Donald Holms Preparation which inhibits the autoimmune response in HIV, or SLE, patients
US6613536B1 (en) * 1995-03-28 2003-09-02 Yeda Research And Development Co. Ltd. Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
IL113159A0 (en) * 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
US20020054872A1 (en) * 1997-03-20 2002-05-09 Yaakov Naparstek Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus
IL120503A0 (en) * 1997-03-20 1997-07-13 Hadasit Med Res Service Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them
ES2302363T3 (es) * 1997-12-18 2008-07-01 Boehringer Ingelheim Pharmaceuticals Inc. Piridonas como inhibidores del dominia sh2 del grupo src.
KR100261262B1 (ko) * 1998-02-03 2000-08-01 윤종용 반도체 습식 설비의 구조 및 이의 로트 로딩/언로딩 방법
US6415877B1 (en) * 1998-07-15 2002-07-09 Deep Vision Llc Subsea wellbore drilling system for reducing bottom hole pressure
CA2427858A1 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
EP1594434B1 (de) * 2003-01-14 2016-09-07 Yeda Research and Development Co. Parenterale peptidformulierungen zur behandlung von systemischem lupus erythematodes
KR20050100616A (ko) * 2003-01-14 2005-10-19 테바 파마슈티컬 인더스트리즈 리미티드 전신성 홍반성 낭창의 치료를 위한 펩티드의 비경구 제제

Also Published As

Publication number Publication date
NO20033718D0 (no) 2003-08-21
PL373520A1 (en) 2005-09-05
CA2439051A1 (en) 2002-09-06
WO2002067848A3 (en) 2002-12-12
CN1309733C (zh) 2007-04-11
AU2002233618B2 (en) 2006-12-21
KR20030092004A (ko) 2003-12-03
US7858738B2 (en) 2010-12-28
JP4316886B2 (ja) 2009-08-19
PT1370575E (pt) 2007-01-31
EA009465B1 (ru) 2007-12-28
CN1503806A (zh) 2004-06-09
CA2439051C (en) 2010-02-02
CU23276B7 (es) 2008-04-09
DK1370575T3 (da) 2007-01-29
ECSP034743A (es) 2004-01-28
IS6908A (is) 2003-08-11
US20040127408A1 (en) 2004-07-01
DE60216243D1 (de) 2007-01-04
HU230372B1 (hu) 2016-03-29
JP2005505493A (ja) 2005-02-24
EP1370575A2 (de) 2003-12-17
US20080119390A1 (en) 2008-05-22
DE60216243T2 (de) 2007-10-31
IL157550A (en) 2010-05-31
SI1370575T1 (sl) 2007-04-30
HRP20030667A2 (en) 2005-06-30
EP1370575B1 (de) 2006-11-22
WO2002067848A2 (en) 2002-09-06
IL157550A0 (en) 2004-03-28
NO20033718L (no) 2003-10-09
EP1370575A4 (de) 2004-09-29
ES2275832T3 (es) 2007-06-16
KR100860735B1 (ko) 2008-09-29
EA200300939A1 (ru) 2004-12-30
NZ527499A (en) 2005-12-23
BR0207586A (pt) 2006-11-07
IL141647A0 (en) 2002-03-10
HUP0600778A2 (en) 2007-01-29
MXPA03007622A (es) 2004-09-14
HK1059790A1 (en) 2004-07-16
NO331820B1 (no) 2012-04-10
ZA200305874B (en) 2005-08-31
CR7058A (es) 2004-11-01
HUP0600778A3 (en) 2012-09-28

Similar Documents

Publication Publication Date Title
DE60216243D1 (de) Synthetische humane peptide und diese enthaltende pharmazeutische zusammensetzungen zur behandlung von systemischem lupus erythematodes
ATE354655T1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
NO962664L (no) Forbindelser med veksthormonfrigjörende egenskaper
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
HRP20130078T1 (hr) Antagonistiäśki mutant protutijela za cd40
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
WO2004066932A3 (en) Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
EA200201214A1 (ru) Замещенные тиоацетамиды
ECSP034714A (es) Moleculas de enlace terapeuticas
ATE339205T1 (de) (3-ä3-'(2,4-bis-trifluormethyl-benzyl)-(5-ethyl pyrimidin-2-yl)-amino)-propoxyü-phenyl)- essigsäure und verwandte verbindungen als modulatoren von ppars und verfahren zur behandlung von stoffwechselstörungen
DE60233433D1 (de) PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN
ATE377026T1 (de) Behandlung von fettleibigkeit
ATE211391T1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
EA200400134A1 (ru) Терапевтический агент
ATE425762T1 (de) Mittel zur behandlung von augentrockenheit und damit zusammenhangenden erkrankungen
DE69630682D1 (de) Synthetische peptide und diese enthaltende arzneimittel zur behandlung des systemischen lupus erythematodes
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
DE60318423D1 (de) Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern
ATE318591T1 (de) Pharmazeutische zusammensetzung zur behandlung von fettleibigkeit
WO2003029290A1 (en) Drug transporter and use thereof
TH42174A3 (th) แอนติบอดีที่ทำให้เหมือนมนุษย์ซึ่งจำเพาะสำหรับ 4-1bb ของมนุษย์และสารผสมทางเภสัชกรรม ซึ่งประกอบด้วยสิ่งเดียวกัน
RU2003109357A (ru) Лекарственное средство для лечения болезней суставов
RU93045696A (ru) Ингибиторы протеазы вируса иммунодефицита человека, полезные для лечения спида

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1370575

Country of ref document: EP